Skip to main content
Erschienen in: Annals of Surgical Oncology 13/2022

04.09.2022 | Hepatobiliary Tumors

Surveillance Patterns for Hepatocellular Carcinoma among Screening-Eligible Patients in the Medicare Population

verfasst von: Marianna V. Papageorge, MD, MPH, Susanna W. L. de Geus, MD, PhD, Alison P. Woods, MD, Sing Chau Ng, MS, Samuel Lee, BS, David McAneny, MD, Jennifer F. Tseng, MD, MPH, Kelly M. Kenzik, PhD, Teviah E. Sachs, MD, MPH

Erschienen in: Annals of Surgical Oncology | Ausgabe 13/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Routine screening plays a critical role in the diagnosis of hepatocellular carcinoma (HCC), but not all patients undergo consistent surveillance. This study aims to evaluate surveillance patterns and their association with diagnosis stage and survival among Medicare patients at risk for HCC.

Patients and Methods

Patients with HCC and guideline-based screening eligibility who underwent imaging with ultrasound or abdominal magnetic resonance imaging (MRI) in the 2 years prior to diagnosis were identified from SEER-Medicare (2008–2015). Three surveillance cohorts were created: diagnostic (imaging only within 3 months prior), intermittent (imaging only once within 2 years prior, excluding diagnostic), and routine (at least two imaging encounters within 2 years prior, excluding diagnostic). Multivariable logistic regression was used to predict early-stage diagnosis (stage I–II), and 5-year survival was evaluated using the accelerated failure time method with Weibull distribution.

Results

Among 2261 eligible patients, 26.1% were classified as diagnostic, 15.8% as intermittent, and 58.1% as routine surveillance. The median age was 74 years (IQR 70–78 years). The majority of patients had a preexisting cirrhosis diagnosis (81.5%). Routine and intermittent, compared with diagnostic, surveillance were predictive of early-stage disease (routine: OR 2.05, 95% CI 1.64–2.56; intermittent: OR 1.43, 95% CI 1.07–1.90). Patients who underwent routine surveillance had significantly lower risk of mortality (HR 0.84, 95% CI 0.75–0.94) compared with the diagnostic group.

Conclusions

A large proportion of screening-eligible patients do not undergo routine surveillance, which is associated with late-stage diagnosis and higher risk of mortality. These findings demonstrate the impact of timely and consistent healthcare access and can guide interventions for promoting surveillance among these patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Cronin KA, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2018;124(13):2785–800.CrossRefPubMed Cronin KA, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2018;124(13):2785–800.CrossRefPubMed
2.
Zurück zum Zitat Mittal, S. and H.B. El-Serag. Epidemiology of hepatocellular carcinoma: consider the population. J Clinical Gastroenterol. 2013. 47 Suppl(0): p. S2–S6. Mittal, S. and H.B. El-Serag. Epidemiology of hepatocellular carcinoma: consider the population. J Clinical Gastroenterol. 2013. 47 Suppl(0): p. S2–S6.
3.
Zurück zum Zitat Brunot A, et al. Hepatocellular carcinoma in elderly patients: challenges and solutions. J Hepatocell Carcinom. 2016;3:9–18.CrossRef Brunot A, et al. Hepatocellular carcinoma in elderly patients: challenges and solutions. J Hepatocell Carcinom. 2016;3:9–18.CrossRef
4.
Zurück zum Zitat Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.CrossRefPubMed Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.CrossRefPubMed
5.
Zurück zum Zitat Marrero JA, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50.CrossRefPubMed Marrero JA, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50.CrossRefPubMed
6.
Zurück zum Zitat Singal, A.G., et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a systematic review and meta-analysis. J Hepatol. 2022. Singal, A.G., et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a systematic review and meta-analysis. J Hepatol. 2022.
7.
Zurück zum Zitat Tran SA, et al. Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis. BMJ Open Gastroenterol. 2018;5(1):e000192.CrossRefPubMedPubMedCentral Tran SA, et al. Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis. BMJ Open Gastroenterol. 2018;5(1):e000192.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Yang JD, et al. Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. Cancer. 2017;123(1):81–9.CrossRefPubMed Yang JD, et al. Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States. Cancer. 2017;123(1):81–9.CrossRefPubMed
9.
Zurück zum Zitat Trevisani, F., et al. Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol. 2004. 99(8). Trevisani, F., et al. Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol. 2004. 99(8).
10.
Zurück zum Zitat Farvardin S, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65(3):875–84.CrossRefPubMed Farvardin S, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65(3):875–84.CrossRefPubMed
11.
Zurück zum Zitat Kronenfeld JP, Goel N. An analysis of individual and contextual-level disparities in screening, treatment, and outcomes for hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1209–19.CrossRefPubMedPubMedCentral Kronenfeld JP, Goel N. An analysis of individual and contextual-level disparities in screening, treatment, and outcomes for hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1209–19.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Elixhauser A, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.CrossRefPubMed Elixhauser A, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.CrossRefPubMed
15.
Zurück zum Zitat van Walraven C, et al. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626–33.CrossRefPubMed van Walraven C, et al. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626–33.CrossRefPubMed
17.
Zurück zum Zitat van Meer S, et al. Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands. J Hepatol. 2015;63(5):1156–63.CrossRefPubMed van Meer S, et al. Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands. J Hepatol. 2015;63(5):1156–63.CrossRefPubMed
18.
Zurück zum Zitat Beste LA, et al. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol. 2015;13(1):172–9.CrossRefPubMed Beste LA, et al. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol. 2015;13(1):172–9.CrossRefPubMed
19.
Zurück zum Zitat Davila JA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52(1):132–41.CrossRefPubMed Davila JA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52(1):132–41.CrossRefPubMed
20.
Zurück zum Zitat Zhao C, et al. Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020;32(3):406–19.CrossRefPubMed Zhao C, et al. Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020;32(3):406–19.CrossRefPubMed
21.
Zurück zum Zitat Sun J, Perraillon MC, Myerson R. The Impact of Medicare Health Insurance Coverage on Lung Cancer Screening. Med Care. 2022;60(1):29–36.CrossRefPubMed Sun J, Perraillon MC, Myerson R. The Impact of Medicare Health Insurance Coverage on Lung Cancer Screening. Med Care. 2022;60(1):29–36.CrossRefPubMed
22.
23.
Zurück zum Zitat Meyer CP, et al. The impact of Medicare eligibility on cancer screening behaviors. Prev Med. 2016;85:47–52.CrossRefPubMed Meyer CP, et al. The impact of Medicare eligibility on cancer screening behaviors. Prev Med. 2016;85:47–52.CrossRefPubMed
24.
Zurück zum Zitat Powell, J., et al., Adherence to hepatitis c therapy in a shelter-based education and treatment model among persons experiencing homelessness. Open Forum Infect Dis. 2021. 8(10). Powell, J., et al., Adherence to hepatitis c therapy in a shelter-based education and treatment model among persons experiencing homelessness. Open Forum Infect Dis. 2021. 8(10).
25.
Zurück zum Zitat Jain MK, et al. Evaluation of a multifaceted intervention to reduce health disparities in hepatitis c screening: a pre-post analysis. Hepatology. 2019;70(1):40–50.PubMed Jain MK, et al. Evaluation of a multifaceted intervention to reduce health disparities in hepatitis c screening: a pre-post analysis. Hepatology. 2019;70(1):40–50.PubMed
26.
Zurück zum Zitat The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med. 2014. 161(3): p. 170–180. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med. 2014. 161(3): p. 170–180.
27.
Zurück zum Zitat Keating NL, et al. Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol. 2006;24(1):85–94.CrossRefPubMed Keating NL, et al. Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol. 2006;24(1):85–94.CrossRefPubMed
28.
Zurück zum Zitat Neugut AI, et al. Adherence to colonoscopy at 1 year following resection of localized colon cancer: a retrospective cohort study. Therap Adv Gastroenterol. 2018;11:1756284818765920.CrossRefPubMedPubMedCentral Neugut AI, et al. Adherence to colonoscopy at 1 year following resection of localized colon cancer: a retrospective cohort study. Therap Adv Gastroenterol. 2018;11:1756284818765920.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Hines RB, et al. The association between post-treatment surveillance testing and survival in stage II and III colon cancer patients: An observational comparative effectiveness study. BMC Cancer. 2019;19(1):418–418.CrossRefPubMedPubMedCentral Hines RB, et al. The association between post-treatment surveillance testing and survival in stage II and III colon cancer patients: An observational comparative effectiveness study. BMC Cancer. 2019;19(1):418–418.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Tseng P-L, et al. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol. 2010;25(8):1426–34.CrossRefPubMed Tseng P-L, et al. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol. 2010;25(8):1426–34.CrossRefPubMed
32.
Zurück zum Zitat Singal AG, et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med. 2015;128(1):90.e1-90.e7.CrossRef Singal AG, et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med. 2015;128(1):90.e1-90.e7.CrossRef
33.
Zurück zum Zitat Singal AG, et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med. 2012;27(7):861–7.CrossRefPubMedPubMedCentral Singal AG, et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med. 2012;27(7):861–7.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Scaglione S, et al. Association between race/ethnicity and insurance status with outcomes in patients with hepatocellular carcinoma. Dig Dis Sci. 2020;65(6):1669–78.CrossRefPubMed Scaglione S, et al. Association between race/ethnicity and insurance status with outcomes in patients with hepatocellular carcinoma. Dig Dis Sci. 2020;65(6):1669–78.CrossRefPubMed
35.
Zurück zum Zitat Zulman DM, et al. Quality of care for patients with multiple chronic conditions: the role of comorbidity interrelatedness. J Gen Intern Med. 2014;29(3):529–37.CrossRefPubMed Zulman DM, et al. Quality of care for patients with multiple chronic conditions: the role of comorbidity interrelatedness. J Gen Intern Med. 2014;29(3):529–37.CrossRefPubMed
36.
Zurück zum Zitat Goldberg DS, et al. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology. 2017;65(3):864–74.CrossRefPubMed Goldberg DS, et al. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology. 2017;65(3):864–74.CrossRefPubMed
37.
Zurück zum Zitat Patwardhan V, et al. Hepatocellular carcinoma screening rates vary by etiology of cirrhosis and involvement of gastrointestinal sub-specialists. Dig Dis Sci. 2011;56(11):3316.CrossRefPubMedPubMedCentral Patwardhan V, et al. Hepatocellular carcinoma screening rates vary by etiology of cirrhosis and involvement of gastrointestinal sub-specialists. Dig Dis Sci. 2011;56(11):3316.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Papageorge, M.V., et al. Beyond insurance status: the impact of Medicaid expansion on the diagnosis of Hepatocellular Carcinoma. HPB (Oxford). 2022. Papageorge, M.V., et al. Beyond insurance status: the impact of Medicaid expansion on the diagnosis of Hepatocellular Carcinoma. HPB (Oxford). 2022.
Metadaten
Titel
Surveillance Patterns for Hepatocellular Carcinoma among Screening-Eligible Patients in the Medicare Population
verfasst von
Marianna V. Papageorge, MD, MPH
Susanna W. L. de Geus, MD, PhD
Alison P. Woods, MD
Sing Chau Ng, MS
Samuel Lee, BS
David McAneny, MD
Jennifer F. Tseng, MD, MPH
Kelly M. Kenzik, PhD
Teviah E. Sachs, MD, MPH
Publikationsdatum
04.09.2022
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 13/2022
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12360-z

Weitere Artikel der Ausgabe 13/2022

Annals of Surgical Oncology 13/2022 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.